Evidence map›Paper›PMID 42472297›Full record

ArticleKidney international reports2026

Circulating IgM Does Not Target Common Chemical Adducts in Recurrent FSGS.

Tim Lempfer, Moritz Riesner, Andrea Angeletti, Frank Hullekes, Leonardo V Riella, Emmanuel Zorn, Paolo Cravedi

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tim LempferDepartment of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York City, New York, USA.
Moritz RiesnerDepartment of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York City, New York, USA.
Andrea AngelettiDivision of Nephrology, Dialysis and Transplantation, Istituto Giannina Gaslini IRCCS, Genova, Italy.
Frank HullekesCenter for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Leonardo V RiellaCenter for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Emmanuel ZornDepartment of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York City, New York, USA.
Paolo CravediDepartment of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.

Funding

Innate B cell immunity and antibody-mediated rejection of human kidney allograftsR01AI123342 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Emmanuel Zorn · 2016 to 2026
$3.3M
NIAID NIH HHS R01 AI123342
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42472297
PMCPMC13380100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.